Darapladib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameDarapladib
Drug Alias NameDarapladibum达雷拉迪达雷拉地达拉地SB-480848
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLipoprotein-associated phospholipase A2 inhibitors
TargetsLipoprotein-associated phospholipase A2
Therapy Area/IndicationsAtherosclerosisVascular DiseasesAcute Coronary Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsAtherosclerosisVascular DiseasesAcute Coronary Syndrome +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG